335 related articles for article (PubMed ID: 37000363)
1. A Systematic Review of the Economic and Health-Related Quality of Life Impact of Advanced Therapies Used to Treat Moderate-to-Severe Ulcerative Colitis.
Cichewicz A; Tencer T; Gupte-Singh K; Egodage S; Burnett H; Kumar J
Adv Ther; 2023 May; 40(5):2116-2146. PubMed ID: 37000363
[TBL] [Abstract][Full Text] [Related]
2. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
[TBL] [Abstract][Full Text] [Related]
3. Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costs.
Dignass A; Waller J; Cappelleri JC; Modesto I; Kisser A; Dietz L; DiBonaventura M; Wood R; May M; Libutzki B; Bargo D
J Med Econ; 2020 Apr; 23(4):415-427. PubMed ID: 31858853
[No Abstract] [Full Text] [Related]
4. The impact of biological interventions for ulcerative colitis on health-related quality of life.
LeBlanc K; Mosli MH; Parker CE; MacDonald JK
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD008655. PubMed ID: 26393522
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
Kobayashi T; Hoshi M; Yuasa A; Arai S; Ikeda M; Matsuda H; Kim SW; Hibi T
Pharmacoeconomics; 2023 May; 41(5):589-604. PubMed ID: 36884164
[TBL] [Abstract][Full Text] [Related]
6. A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis.
Stawowczyk E; Kawalec P
Pharmacoeconomics; 2018 Apr; 36(4):419-434. PubMed ID: 29260508
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia.
AlRuthia Y; Almadi M; Aljebreen A; Azzam N; Alsharif W; Alrasheed H; Almuaythir G; Saeed M; HajkhderMullaissa B; Alharbi O
J Med Econ; 2020 Oct; 23(10):1102-1110. PubMed ID: 32619388
[TBL] [Abstract][Full Text] [Related]
8. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
Hernandez L; Kuwabara H; Shah A; Yamabe K; Burnett H; Fahrbach K; Koufopoulou M; Iwakiri R
Pharmacoeconomics; 2020 Jan; 38(1):69-84. PubMed ID: 31552601
[TBL] [Abstract][Full Text] [Related]
10. Indirect costs associated with ulcerative colitis: a systematic literature review of real-world data.
Constantin J; Atanasov P; Wirth D; Borsi A
BMC Gastroenterol; 2019 Nov; 19(1):179. PubMed ID: 31706270
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.
Sardesai A; Dignass A; Quon P; Milev S; Cappelleri JC; Kisser A; Modesto I; Sharma PP
J Med Econ; 2021; 24(1):279-290. PubMed ID: 33502905
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.
Lasa JS; Olivera PA; Danese S; Peyrin-Biroulet L
Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):161-170. PubMed ID: 34856198
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. Assessing the economics of biologic and small molecule therapies for the treatment of moderate to severe ulcerative colitis in Japan: a cost per responder analysis of upadacitinib.
Saruta M; Kawaguchi I; Ogawa Y; Sanchez Gonzalez Y; Numajiri N; Tang X; Miller R
J Med Econ; 2024; 27(1):566-574. PubMed ID: 38512101
[TBL] [Abstract][Full Text] [Related]
15. Golimumab improves work productivity in patients suffering from moderate to severe ulcerative colitis: results of a prospective study over 24 months.
Teich N; Grümmer H; Jörgensen E; Liceni T; Holtkamp-Endemann F; Fischer T; Hohenberger S
BMC Gastroenterol; 2021 Apr; 21(1):161. PubMed ID: 33845784
[TBL] [Abstract][Full Text] [Related]
16. The incidence of remission and indicators of inadequate response to advanced therapy in patients with ulcerative colitis: results from medical charts in the United Kingdom.
Lindsay JO; Picker N; Kromer D; Smyth M; Patel H
Curr Med Res Opin; 2023 May; 39(5):681-689. PubMed ID: 36951899
[TBL] [Abstract][Full Text] [Related]
17. Epidemiological, Clinical, Patient-Reported and Economic Burden of Inflammatory Bowel Disease (Ulcerative colitis and Crohn's disease) in Spain: A Systematic Review.
Barreiro-de Acosta M; Molero A; Artime E; Díaz-Cerezo S; Lizán L; de Paz HD; Martín-Arranz MD
Adv Ther; 2023 May; 40(5):1975-2014. PubMed ID: 36928496
[TBL] [Abstract][Full Text] [Related]
18. Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model.
Sutcliffe P; Connock M; Pulikottil-Jacob R; Kandala NB; Suri G; Gurung T; Grove A; Shyangdan D; Briscoe S; Maheswaran H; Clarke A
Health Technol Assess; 2013 Nov; 17(53):1-499, v-vi. PubMed ID: 24280231
[TBL] [Abstract][Full Text] [Related]
19. Real-World Patterns and Economic Burden Associated With Treatment Failure With Advanced Therapies in Patients With Moderate-to-Severe Ulcerative Colitis.
Lee SD; Betts KA; Xiaoyan Du E; Nie X; Gupte-Singh K; Ritter T
Crohns Colitis 360; 2024 Apr; 6(2):otae026. PubMed ID: 38751576
[TBL] [Abstract][Full Text] [Related]
20. Optimal treatment sequence for targeted immune modulators for the treatment of moderate to severe ulcerative colitis.
Bloudek LM; Pandey R; Fazioli K; Ollendorf DA; Carlson JJ
J Manag Care Spec Pharm; 2021 Aug; 27(8):1046-1055. PubMed ID: 34337994
[No Abstract] [Full Text] [Related]
[Next] [New Search]
